We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Request Information

To request more information about this product, please complete the form below.

Scientist working with lab equipment and microplate for CHO cell line development in biopharmaceutical research.
Credit: Evotec
Request Information
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
Featured Product
Advertisement

Just-Evotec Biologics Mammalian Expression System for Continuous Manufacturing

Just-Evotec Biologics Mammalian Expression System for Continuous Manufacturing
Credit: Evotec

Just-Evotec Biologics is helping partners with antibody product candidates achieve the highest product quality with Cost of Goods Manufactured (COGM) below $50/g by combining its new J.CHO™ High Expression System (J.CHO™) with its unique continuous manufacturing platform. This extraordinary productivity represents a 75% reduction in industry standard COGM and is driven by the exceptionally high titers exceeding 4g/L/day in perfusion achieved utilizing J.CHO™. This performance is equivalent to a titer of approximately 30 g/L in fed-batch mode.


The J.CHO™ High Expression System comprises:


  • Engineered GS knockout CHO-K1 host cell lines capable of delivering specific productivities more than 50 pg/cell/day and growing at target densities of 60-100 million cells/mL
  • Transposon-based expression vectors with strong promoter sequences allowing stable integration and high expression of genes-of-interest (GOI)
  • Proprietary chemically defined, protein-free and dual sourced perfusion cell culture media designed with cost-efficiency in mind.


Just-Evotec Biologics developed product sales royalty-free cell lines to work perfectly with our upstream perfusion platform process and to scale seamlessly from 3L to 500L or 1000L bioreactors for clinical or commercial production.